Bachem Holding AG (BANB.SW) — Quality & forensics
As of 2026-10-29 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 33
- Quality 43
- Growth 39
- Balance sheet 77
- Cash quality 57
- Capital allocation 48
- Momentum 82
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the BANB.SW chart & overview
FAQ · from the current data · as of 2026-10-29
Quick answers
What is Bachem Holding AG's Closelooknet quality reading?
The composite reads 52/100 across 7 modules, as of 2026-10-29: valuation 33, quality 43, growth 39, balance sheet 77, cash quality 57, capital allocation 48, momentum 82. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Bachem Holding AG's Altman Z-Score?
7.08, which sits in the safe zone (above 2.99) as of 2026-10-29. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Bachem Holding AG's Piotroski F-Score?
6 of 8, as of 2026-10-29. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Bachem Holding AG's Beneish M-Score indicate?
-2.86 — below the −1.78 manipulation-risk threshold, as of 2026-10-29. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- HALO Halozyme Therapeutics Incindustry
- UCB.BR UCB SAindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- RIGL Rigel Pharmaceuticals Incindustry
- KOD Kodiak Sciences Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- REPL Replimune Group Incindustry
- ABSI Absci Corpindustry
- MRNA Moderna Incindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- BHVN Biohaven Ltd.industry
- ARQT Arcutis Biotherapeutics Incindustry
- ADMA ADMA Biologics Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- SEPN Septerna, Inc. Common Stockindustry
- IRON Disc Medicine Inc.industry
- RXRX Recursion Pharmaceuticals Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry